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ORIGINAL ARTICLE
Serotonin tranporter methylation and response to cognitive
behaviour therapy in children with anxiety disorders
S Roberts1, KJ Lester1, JL Hudson2, RM Rapee2, C Creswell3, PJ Cooper3,4, KJ Thirlwall3, JRI Coleman1, G Breen1, CCY Wong1,5 and
TC Eley1,5
Anxiety disorders that are the most commonly occurring psychiatric disorders in childhood, are associated with a range of social
and educational impairments and often continue into adulthood. Cognitive behaviour therapy (CBT) is an effective treatment
option for the majority of cases, although up to 35–45% of children do not achieve remission. Recent research suggests that some
genetic variants may be associated with a more beneﬁcial response to psychological therapy. Epigenetic mechanisms such as DNA
methylation work at the interface between genetic and environmental inﬂuences. Furthermore, epigenetic alterations at the
serotonin transporter (SERT) promoter region have been associated with environmental inﬂuences such as stressful life experiences.
In this study, we measured DNA methylation upstream of SERT in 116 children with an anxiety disorder, before and after receiving
CBT. Change during treatment in percentage DNA methylation was signiﬁcantly different in treatment responders vs
nonresponders. This effect was driven by one CpG site in particular, at which responders increased in methylation, whereas
nonresponders showed a decrease in DNA methylation. This is the ﬁrst study to demonstrate differences in SERT methylation
change in association with response to a purely psychological therapy. These ﬁndings conﬁrm that biological changes occur
alongside changes in symptomatology following a psychological therapy such as CBT.
Translational Psychiatry (2014) 4, e444; doi:10.1038/tp.2014.83; published online 16 September 2014
INTRODUCTION
Anxiety disorders have negative implications for many aspects of
everyday functioning.1,2 They often arise during childhood and are
not only associated with adult anxiety disorders but also with
other forms of adult psychopathology such as depression.3,4
Cognitive behaviour therapy (CBT) is an effective treatment option
for child and adolescent anxiety disorders with a remission rate of
56% following treatment, rising to around 65% at follow-up.5,6
Research exploring predictors of response to CBT in childhood
anxiety disorders is somewhat mixed, but provides modest
support for factors such as pretreatment symptom severity,
comorbidity and parental psychopathology.7–10 These factors are
consistent with a possible genetic basis to CBT response.
Multiple genetic markers have been investigated for association
with anxiety disorders and depression. Due to the success of
anxiolytic and antidepressant drugs that target the serotonin
transporter system11,12 and the critical role of the serotonin
transporter in the termination of serotonergic neurotransmission,
polymorphic variants of the serotonin transporter gene (SERT)
have been widely studied. One of the best characterized of these
variants is the serotonin transporter-linked polymorphic region,
5HTTLPR, which consists of a 43/44 bp insertion/deletion
upstream of the transcription start site.13,14 Meta-analyses suggest
that the short allelic variant of this region is associated with higher
levels of anxiety and other related traits.15 This association is also
subject to environmental inﬂuence, with studies of gene × envir-
onment interactions showing that the short allele carriers have the
poorest outcomes (the highest levels of anxiety and depression) in
high-stress, negative environments.16,17 However, individuals
homozygous for the short allele also display better outcomes in
low stress environments,18–22 suggesting that 5HTTLPR may
represent an example of ‘Differential Susceptibility’, or a higher
sensitivity to environmental inﬂuences.23
Therapies such as CBT provide an excellent setting in which to
explore environmental inﬂuences in a gene× environment inter-
action context as the timing of treatment is known, allowing for
prospective assessment of the association between symptoms
and genetic factors.24 Previously, we published data showing a
signiﬁcant association between 5HTTLPR genotype and response
to CBT in children with anxiety disorders.25 At follow-up,
compared with L allele carriers, children homozygous for the
short allele were 20% more likely to be free of their primary
anxiety disorder diagnosis, and 18.8% more likely to be free of all
anxiety disorder diagnoses.25 Children homozygous for the short
allele also showed a signiﬁcantly greater reduction in symptom
severity than those with one or more long alleles. These ﬁndings
reﬂect an interaction between genetic (5HTTLPR) and environ-
mental (CBT) inﬂuences on outcome.
Epigenetic mechanisms such as DNA methylation are thought
to work at the interface between genes and the environment as
they are sensitive to changes in environmental stimuli. The SERT
promoter region has been shown to be particularly variable in
DNA methylation across time,26 and differential DNA methylation
patterns at this region have been associated with a range of
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negative life experiences. A study of SERT DNA methylation in
adoptees found altered methylation patterns in those who
experienced a range of negative life events and stressful situations
such as child abuse and loss.27–29 In the case of unresolved loss or
trauma, changes in DNA methylation associated with outcome
were dependent on 5HTTLPR genotype. Monozygotic twins offer
the opportunity to study the effects of environmental inﬂuences
on SERTmethylation while controlling for genetics. For example, in
a study of monozygotic twins discordant for bullying victimization,
increased SERT methylation patterns were identiﬁed in the bullied
twins compared with their co-twins with no history of bullying.30
The investigation of DNA methylation and outcome following
psychological therapy is a new area of research. One previous
study of participants with borderline personality disorders
(n= 115) suggested an association between poorer response to
intensive dialectical behaviour therapy and increases in DNA
methylation of the brain-derived neurotrophic factor gene.31
Another study of veterans with posttraumatic stress disorder
(n= 16) found that higher pretreatment glucocorticoid-related
NR3C1 methylation predicted treatment outcome, whereas FKBP5
gene methylation decreased across treatment time in association
with recovery.32 However, some participants were also medicated
in both studies.
In this study, we compared SERT DNA methylation change from
pre- to post-treatment in 116 children receiving CBT for an anxiety
disorder. Speciﬁcally, we compared mean changes in methylation
during the treatment period for those who had and had not
remitted from their primary anxiety disorder by the end of
treatment and by the follow-up time point (6 months after the end
of treatment). To our knowledge, this is the ﬁrst study of response
to a purely psychological therapy and changes in DNA methylation
to focus on the SERT promoter region. Given the role played by
DNA methylation in mediating the effect of the environment on
emotional and behavioural outcomes, and previous ﬁndings that
5HTTLPR genotype is associated with treatment response, we
hypothesized that treatment outcome would be associated with
SERT DNA methylation changes during treatment.
MATERIALS AND METHODS
Participants
Sample. Participants (n= 116) represent a subsample of a larger long-
itudinal study exploring genetic predictors of therapy response. Subjects
were recruited at clinical sites in Sydney, Australia (n= 88) and Reading, UK
(n=28), and provided buccal swab DNA samples at assessment sessions
pre- and post-treatment, within 2 weeks of the ﬁrst and last treatment
session, respectively. Participants ranged in age from 6 to 13 years (mean
age= 9.34 years); 51.7% were male. All children completed a full course of
manual-based CBT for a primary diagnosis of an anxiety disorder. Details of
the speciﬁc treatment protocols at each site have been reported
elsewhere.25 All trials and collection of samples were approved by Human
Ethics and Biosafety Committees at both clinical sites. Parents provided
informed consent, children provided assent. The storage and analysis of
DNA for this study were approved by the Psychiatry, Nursing and
Midwifery Research Ethics Sub-Committee at King’s College London,
London, UK.
Anxiety disorder diagnoses. Participants were diagnosed according to the
Anxiety Disorders Interview Schedule for DSM-IV, Child and Parent Versions
(ADIS-IV-C/P),33 and severity ratings (0–8) were made by graduate or
clinical psychologists on the basis of composite parent and child reports.
Anxiety disorder diagnoses corresponded to a clinical severity rating of 4
or greater. Clinical diagnoses were made at assessment sessions pre- and
post-treatment, and also at a follow-up time point (6 months after the
conclusion of treatment). Details of sample characteristics and primary
anxiety disorder diagnoses made can be found in Table 1.
Methods
DNA preparation. DNA was collected at pre- and post-treatment using
buccal swabs, and extracted using established procedures designed to
maximize the purity and yield of DNA from the sample.34 Extracted
genomic DNA (510 ng) was treated with sodium bisulphite using the EZ-96
DNA Methylation Kit (Zymo Research, Orange, CA, USA).
Bisulphite PCR. The SERT region targeted in this study is situated upstream
of the promoter. To aid ampliﬁcation, the sequence was split into two
smaller, overlapping amplicons of 200 and 296 bp that covered the whole
region (NCBI build 37, chromosome 17; (1) 28562753–28563048, (2)
28563022–28563221, see Supplementary Information, Figure 1a).
Bisulphite-PCR primers for each amplicon were designed using the
Sequenom EpiDesigner software. PCR ampliﬁcation was conducted using
45 cycles at an annealing temperature of 56 °C, with Qiagen Hot Star Taq
DNA Polymerase (Qiagen, UK) and Sequenom MassCLEAVE tagged primers
(Primer sequences in Supplementary Information Table 1, amplicon
sequences in Supplementary Information Figure 1b). Each PCR was
performed in duplicate for both amplicons per sample, and the PCR
products pooled by amplicon to minimize PCR bias.
Sequenom EpiTYPER. DNA methylation was quantitatively measured using
the Sequenom EpiTYPER system (Sequenom, San Diego, CA, USA), which
has been described previously.35 The sample reported (n= 116) refers to
samples that had bisulphite-PCR product available for both pre- and
posttreatment time points.
Quality control. Artiﬁcially fully methylated and unmethylated samples
were included as assay controls. Probes detecting an average methylation
of o5% were excluded from any analyses. Following stringent quality
control, quantitative methylation data from six CpG sites was obtained.
Analyses. We considered two measures of treatment response. First was
primary anxiety response, deﬁned as the absence of the primary anxiety
diagnosis. Second was a broad anxiety response, deﬁned as the absence of
all anxiety diagnoses. Clinical outcome was assessed at posttreatment and
at follow-up (6 months after treatment). Average DNA methylation was
calculated where data were available for at least ﬁve probes at both time
Table 1. Sample characteristics
Sample characteristics
Clinical site
Sydney n= 88 (75.9%)
Reading n= 28 (24.1%)
Age
Range (mean) 6–13 (9.34)
Primary anxiety diagnosis
Generalized anxiety disorder n= 56 (48.3%)
Speciﬁc phobia n= 20 (17.2%)
Separation anxiety disorder n= 16 (13.8%)
Social anxiety disorder n= 14 (12.1%)
Obsessive compulsive disorder n= 9 (7.8%)
Panic disorder/agoraphobia n= 1 (0.9%)
Gender
Male n= 60 (51.7%)
Female n= 56 (48.3%)
Treatment group
Individual CBT n= 95 (81.9%)
Group CBT n= 9 (7.8%)
Guided self help (e.g., bibliotherapy with therapist
support)
n= 12 (10.3%)
Abbreviation: CBT, cognitive behaviour therapy.
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points. Change in DNA methylation during treatment (from pre- to
posttreatment) was calculated for all CpG sites, and also as an average
across the region. All analyses were performed in SPSS (version 20.0, IBM
Corp, Armonk, NY, USA).
To correct for multiple testing, a revised signiﬁcance threshold was
calculated using Matrix Spectral Decomposition.36 This method uses
correlation between methylation levels at the CpG sites to give an effective
number of independent variables to correct for. In our data, the estimated
number of independent variables was 5.641, corresponding with a
signiﬁcant threshold of P= 0.009.
RESULTS
Clinical outcome was in line with previous estimates. For primary
and all anxiety diagnoses, remission rates were 48.3 and 29.3% at
posttreatment, and 70.7 and 51.7% at follow-up (Table 2).
Percentage DNA methylation at pre- and posttreatment was not
signiﬁcantly different in the whole group at any CpG sites
(Supplementary Table 2). However, there were signiﬁcant
differences between responders and nonresponders.
For primary anxiety response, those deﬁned as responders at
follow-up showed a small increase in SERT methylation during the
treatment period (from pre- to posttreatment, +1.1%) at CpG site
4, whereas nonresponders showed a larger decrease in methyla-
tion (nominally signiﬁcant;− 5.9%, t(91) = 2.114, P= 0.037,
d= 0.499; see Figure 1a). The difference in DNA methylation
change as an average across the whole region was
not statistically signiﬁcant between responders and nonrespon-
ders (t(114) = 1.904, P= 0.059, d= 0.395). When split by primary
anxiety response at posttreatment, responders and nonrespon-
ders did not differ signiﬁcantly in change in methylation (all sites
average: t(107) =− 0.363, P= 0.717, d=− 0.070. CpG site 4: t
(87) = 0.021, P= 0.984, d= 0.000). Finally, when looking at change
in symptom severity for the primary anxiety disorder from
posttreatment to follow-up, there was a signiﬁcant difference in
average DNA methylation change (during treatment) across the
region between participants who continued to improve from
posttreatment to follow-up and those who showed no improve-
ment or worsened (t(95.45) = 3.067, P= 0.003, d= 0.591).
For all anxiety response, there was a signiﬁcant difference
between treatment responders and nonresponders at follow-up in
average DNA methylation change during treatment (Figure 1: t
(114) = 2.981, P= 0.004, d= 0.554). This effect was driven by CpG
site 4 in particular (Figure 1: t(91) = 3.146, P= 0.002, d= 0.65). At
this CpG site, responders showed an increase in methylation
during treatment (mean change =+3.48%), whereas nonrespon-
ders showed a decrease in methylation during treatment (mean
change =− 5.44%). (The same pattern of results for all tests was
detected when including an additional participant on a stable
dose of anxiety medication (reported in Supplementary
Information).)
Of note, when split by response at posttreatment, all anxiety
responders and nonresponders did not differ signiﬁcantly in
change in methylation (all sites average: t(110) =− 0.700, P= 0.486,
d=− 0.089. CpG site 4: t(87) =− 0.400, P= 0.690, d= 0.140).
There were no signiﬁcant differences in DNA methylation
change at CpG site 4 or average methylation change across the
region between participants split by age (older vs younger),
gender or treatment site (test statistics; see Supplementary Table
3). Treatment response groups (responders vs nonresponders for
both primary anxiety outcome and all anxiety outcome, and
improvers vs those who did not during the follow-up period for
primary anxiety outcome) did not differ on any demographic
variables tested (Supplementary Table 3).
DISCUSSION
Our ﬁndings suggest that treatment responders and nonrespon-
ders have differential patterns of methylation change across a
course of CBT. Responders showed an increase in percentage DNA
methylation during treatment at one CpG site in the SERT
promoter region, whereas nonresponders decreased in percen-
tage DNA methylation. The results of the current study are
comparable to those reported by a previous study of response to
psychological therapy in borderline personality disorder, where
responders and nonresponders showed a difference in the
direction of change in brain-derived neurotrophic factor DNA
methylation.31
Interestingly, this effect was not observable when participants
were split by treatment outcome at posttreatment. However, there
was a signiﬁcant difference in average DNA methylation change
across the region between those who continued to improve
during the follow-up period, and those who worsened. The period
between posttreatment and follow-up typically represents a
period of consolidation, where the child continues to practice
the skills and techniques they have learnt and developed during
Figure 1. Change in DNA methylation from pre- to posttreatment in
treatment repsonders and nonresponders by CpG site. (a) Primary
anxiety responders, *Po0.05. (b) All anxiety responders **P= 0.004,
***P= 0.002.
Table 2. Treatment outcome
Treatment outcome—free of diagnosis
Posttreatment
Primary anxiety disorder n= 56 (48.3%)
All anxiety disorder diagnoses n= 34 (29.3%)
Follow-up
Primary anxiety disorder n= 82 (70.7%)
All anxiety disorder diagnoses n= 60 (51.7%)
SERT methylation change and response to CBT
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treatment. These results are in line with previous research from
our team that found no effect of genotype immediately
posttreatment, but that individuals homozygous for the S allele
of the 5HTTLPR were 20% more likely to respond to CBT at follow-
up.25
In this study, signiﬁcant differences in DNA methylation change
during treatment were found for those free of all anxiety disorder
diagnoses at follow-up, but not for those only free of their primary
anxiety diagnosis. Effect sizes using the all anxiety response
measures were medium, but were small to medium for primary
anxiety response.37 These ﬁndings suggest that the association
between DNA methylation change and treatment response is
strongest for those who are more general responders, rather than
those whose response is disorder speciﬁc.
Psychological therapies such as CBT involve exposing the
individual to the feared stimuli, and helping them to change the
thought processes that surround fear and anxiety-provoking
situations. Neuroimaging studies of CBT in anxiety disorders have
demonstrated that there are functional changes in brain activation
patterns across the course of treatment, and furthermore that
these patterns are associated with differential response to
CBT.38–44 The ﬁndings that changes in neural activation patterns
are associated with psychological outcomes, such as fear
responses and remission, provide evidence that CBT is associated
with biological processes. Studies in both humans and macaques
have implied that epigenetic regulation of the SERT promoter
region is associated with levels of SERT gene expression and
differences in behaviour following environmental stress.28,45–47
Higher DNA methylation is often (though not always) associated
with reduced gene expression.48,49 In this study, we ﬁnd that
anxious children who respond to CBT have increased levels of
SERT DNA methylation over time. It is possible that this increase in
methylation may correspond with a reduction in expression.
Reduced gene expression is commonly linked with the short allele
of the 5HTTLPR genotype,13 which we have previously shown to
be associated with response to CBT.25 The demonstration that
SERT DNA methylation patterns are associated with differential
outcomes following CBT suggests that this may be a plausible
mechanism by which the biological changes associated with
alterations in thought processes occur.
The results should be considered preliminary as they have not
yet been replicated. This study also has some limitations. First, the
sample is relatively small, and was too small to look at the effect of
genotype. However, we note that the power of the study is
enhanced by the collection of samples from multiple time points.
Second, we have no DNA samples to measure percentage DNA
methylation at the follow-up time point. Given the ﬁndings from
this and earlier studies that response to treatment at follow-up is
associated with both 5HTTLPR genotype and changes in DNA
methylation, future studies investigating potential biological
mechanisms of response would beneﬁt from including DNA
samples at follow-up. Third, the DNA used was derived from
buccal swabs. The design of this study meant that it was necessary
to utilize peripheral tissue samples as they were collected from
living participants at multiple time points. Furthermore, the use of
a child sample precludes other tissues types. However, although
tissue-speciﬁc differences in DNA methylation have been pre-
viously documented,50 recent research suggests that buccal swabs
may be more representative than other peripheral tissues such as
blood, as they have less cell heterogeneity and originate from the
same developmental pathway as brain tissue.51 Finally, we were
not able to measure SERT expression in this sample, and were
therefore unable to investigate the functionality of the observed
changes in DNA methylation at CpG site 4. However, differential
DNA methylation in the SERT promoter region has previously been
shown to be associated with altered gene expression.28
In conclusion, we have demonstrated that DNA methylation
change during treatment is associated with response to CBT in
children with anxiety disorders. The results, which require
replication, support the hypothesis that response to environ-
mental inﬂuences such as psychological therapy is associated with
changes at a biological level.
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